<DOC>
	<DOCNO>NCT01079507</DOCNO>
	<brief_summary>Acute lymphoblastic leukemia ( ALL ) single disease , composite heterogeneous subgroup . Accordingly , sophisticated classification ALL essential achieve improvement treatment outcome . However , genetic marker reveal significant prognostic implication ALL patient . The current study design stratify ALL patient accord prognosis predict outcomes pharmacogenetic approach . A predictive model generate 130 genotype adult ALL patient diagnose Samsung Medical Center ( SMC ) , Sungkyunkwan University School Medicine , Seoul , Korea 1994 2008 . The validation predictive model perform use independent external cohort ALL patient . 1 . Definition cohort : two hundred ALL patient SMC test set , another 100 patient SMC first validation set , another 150 independent external patient second external validation set . DNAs extract stored patient ' sample collect time diagnosis . 2 . In test set , genotype determine use MALDI-TOF base platform ( Sequenom , San Diego , CA , USA ) 130 SNPs candidate gene involve DNA repair pathway , drug metabolism/transport pathway folate metabolism pathway . 3 . Bioinformatic analysis perform identify around 13 genotype ( 10 % ) strong predictive significance 130 SNPs term treatment outcomes , drug toxicity prognosis test set . 4 . These 13 genotype validate first cohort 100 ALL patient use multivariate Cox 's proportional hazard model . 5 . The predictive model build base Cox 's proportional hazard model derive 13 candidate genotype clinical risk factor . 6 . The predictive model base pharmacogenetic information validate second , independent external cohort 150 ALL patient . Definite prognostic value establish genetic molecular marker acute lymphoblastic leukemia ( ALL ) except BCR/ABL fusion gene . The current study attempt build predictive model base single nucleotide polymorphism ( SNPs ) pharmacogenetic approach use 130 genotype multiple candidate pathway DNA repair pathway , drug metabolism / transport pathway folate metabolism pathway . The predictive model base SNPs generate validated respect treatment outcomes , drug toxicity prognosis adult ALL patient . The present study demonstrate : 1 ) Pharmacogenetic information derive SNPs involve DNA repair pathway , drug metabolism/transport pathway folate metabolism pathway , helpful predict treatment outcomes , drug toxicity prognosis ALL patient ; 2 ) Predictive model derive pharmacogenetic information effective reasonable approach stratify ALL patient accord clinical outcome ; 3 ) The SNP-based predictive model could reasonably apply treatment ALL patient , thus become basis improvement treatment outcome ; 4 ) Finally , project enhance facilitate pharmacogenetic research hematology area , thus make team lead pharmacogenetic research world .</brief_summary>
	<brief_title>Genome-wide Single Nucleotide Polymorphism ( SNP ) Array-based Approach Predict Chemoresponse Survival Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>patient core bind factor positive acute myeloid leukemia 18 year old patient treat standard chemotherapy patient available medical record store bone marrow specimen time diagnosis definitive criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>single nucleotide polymorphism</keyword>
	<keyword>adult acute lymphoblastic leukemia</keyword>
</DOC>